Icecure Medical Ltd.宣布，已就Prosense®冷冻消融系统在荷兰市场达成一项独家分销协议。这一战略举措，标志着该公司在欧洲版图上的又一次关键落子。协议的核心，是授予合作方在荷兰境内独家推广与销售Prosense®系统的权利。此举有望显著提升该创新疗法在荷兰的可及性，为当地患者带来新的治疗选择。通过这一合作，Icecure旨在深化其国际布局，并强化其在微创肿瘤治疗领域的市场地位。协议的签署，不仅拓宽了产品的市场通道，也体现了公司对欧洲市场的长期承诺。荷兰作为欧洲医疗技术创新的前沿阵地，此次合作的意义不言而喻。Icecure方面表示，相信凭借合作伙伴在当地深厚的网络与专业经验，能够有效推动Prosense®技术的临床采纳与应用。这一动态，也向业界传递了公司全球化战略稳步推进的积极信号。后续，双方将协同推进产品的市场准入、医师培训及临床推广等各项工作，力求让这一先进技术尽快惠及更多患者。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.